NRF2.com
Back to Research
Gene EditingCancer Drug ResistanceTherapeutics

Gene editing breakthrough offers new hope for head and neck cancer patients

ChristianaCare / CorriXR Therapeutics

Abstract

Expanding on lung cancer CRISPR work, researchers successfully disrupted NRF2 in head and neck cancer and esophageal cancer cell types using CRISPR gene editing. Targeting exon 4 yielded the strongest results, reducing NRF2 levels by 90% and significantly increasing chemotherapy sensitivity.

Key Findings

  • CRISPR-based NRF2 disruption extended to head and neck cancers
  • Targeting NRF2 exon 4 reduced NRF2 protein levels by 90%
  • Significantly increased chemotherapy sensitivity
  • Demonstrates broad applicability across solid tumors

Clinical Significance

Extends NRF2-CRISPR therapy beyond lung cancer to head and neck cancers. The 90% NRF2 reduction represents a major efficiency improvement.

Citation

Banas, K. & Kmiec, E. (2026). Gene editing for head and neck cancer. ChristianaCare.